Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Fosun Pharma to Float up to $470 Million in Bonds

publication date: Nov 25, 2011
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Shanghai Fosun Pharma received permission from the China Securities Regulatory Commission (CSRC) to offer up to 3 billion RMB ($470 million) of corporate bonds. The bonds will be issued in installments. Half of the total must be offered in the first six months, and the remaining amount can be issued during the next 18 months. Fosun Pharma did not disclose how it intends to use the capital. More details....

Stock Symbol: (SHA: 600196)     Share this with colleagues:  

 


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors